Quarton International (“Quarton”) is pleased to announce the sale of shares of evitria AG (“evitria”) to AFINUM Achte Beteiligungsgesellschaft mbH & Co. KG (“AFINUM”) and SHS V Medtech Investments GmbH (“SHS”).
Quarton was the exclusive investment banking advisor to evitria’s shareholder, who will continue to oversee the further expansion of the company, jointly with the new investors.
evitria, headquartered in Schlieren (Switzerland), was founded in 2010 and has become one of the leading providers of custom antibodies for research purposes. With a track record of more than 5,000 antibodies produced for a worldwide client base, evitria sets itself apart with its benchmark-setting speed and reliability. The market in which evitria operates is expected to continue to grow significantly in the coming years and support its further expansion.
evitria is a global antibody expression service provider and is located in Schlieren, Switzerland. The company services a broad range of customers from start-ups and research institutions to world-renowned pharmaceutical and biotech companies.
AFINUM is an independent financial investor wholly-owned by its management with offices in Munich, Zurich, Vienna and Hongkong, specializing in the acquisition of shareholdings in financially sound and successful mid-market companies in the German-speaking region as well as in neighbouring countries in Europe.
SHS is a financial investor based in Tübingen, Germany, specializing in medtech and life sciences companies.
To subscribe to our Newsletter, please use the following link.